<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392558</url>
  </required_header>
  <id_info>
    <org_study_id>DCS-25-17</org_study_id>
    <nct_id>NCT03392558</nct_id>
  </id_info>
  <brief_title>The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea</brief_title>
  <official_title>The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burt's Bees Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dermatology Consulting Services, High Point NC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Burt's Bees Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates a nature-based sensitive skin regimen (NBSSR), as a suitable adjunct
      topical application to prescription medication when administered daily over the course of
      four weeks, in moderate to severe rosacea in comparison to the control regimen (CR).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment of Rosacea Scale Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>The primary efficacy endpoint is no increase in the cumulative Investigator Global Assessment of Rosacea Scale score, measured at Week 4 from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Skin Quality</measure>
    <time_frame>4 weeks</time_frame>
    <description>The secondary efficacy endpoint is at least no increase in the Overall Skin Quality domain of the Subject-Rated Efficacy Scale score, measured at Week 4 from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Transepidermal Water Loss</measure>
    <time_frame>4 weeks</time_frame>
    <description>No increase in transepidermal water loss values measured at Week 4 from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Corneometry</measure>
    <time_frame>4 weeks</time_frame>
    <description>No decrease in corneometry values at Week 4 from baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Nature-Based Sensitive Skin Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Burt's Bees Skin Care Regimen (Nature Based Sensitive Skin Regimen, NBSSR):
Burt's Bees Sensitive Facial Cleanser (to be used day and night)
Burt's Bees Sensitive Daily Moisturizing Cream (to be used in the day)
Burt's Bees Sensitive Night Cream (to be used at night)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Skin Care Regimen (Control Regimen, CR):
Cetaphil Gentle Skin Cleanser (to be used day and night)
Cetaphil Moisturizing Lotion (to be used day and night)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Burt's Bees Skin Care Regimen</intervention_name>
    <description>Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)</description>
    <arm_group_label>Nature-Based Sensitive Skin Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Regimen</intervention_name>
    <description>Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)</description>
    <arm_group_label>Control Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be female 25-60 years of age with moderate facial rosacea at screening
             and 6 or 7 papules and/or pustules; as well as, no other known medical conditions
             that, in the investigator's opinion, may interfere with study participation.

          -  Women of childbearing potential must be willing to use a form of birth control during
             the study. For the purpose of this study, the following are considered acceptable
             methods of birth control: oral contraceptives, Norplant(R), Depo-Provera(R) double
             barrier methods (e.g., condom and spermacide) and abstinence.

          -  Subjects must provide written informed consent.

          -  Willingness to comply with the study design and procedures.

          -  Subjects who agree to sign a photography release form.

        Exclusion Criteria:

          -  Any dermatological disorder, except rosacea requiring the use of prescription
             medication, which in the investigator's opinion, may interfere with the accurate
             evaluation of the subject's skin characteristics,

          -  Subjects who are using any anti-aging skin care products within 4 weeks of study
             enrollment.

          -  Subjects who are not willing to use only the assigned study products and nothing else,
             except for self-selected colored cosmetics that must remain unchanged during the
             study, to their face.

          -  Subjects who have demonstrated a previous hypersensitivity reaction to any of the
             ingredients of the study products.

          -  Subjects, who are pregnant, breast feeding, or planning a pregnancy.

          -  Subjects with clinically significant unstable medical disorders.

          -  Subjects who are unwilling or unable to comply with the requirements of the protocol.

          -  Subjects who have history of a psychological illness or condition that would interfere
             with their ability to understand and follow the requirements of the study.

          -  Subjects who have participated in any clinical study in the past 30 days or are
             currently participating in any other clinical study.

          -  Subjects with any planned surgeries and/or invasive medical procedures during the
             course of the study.

          -  Subjects who started hormone replacement therapies (HRT) or hormones for birth control
             less than 3 months prior to study entry or who plan on starting, stopping, or changing
             doses of HRT or hormones for birth control during the study.

          -  Subjects who currently or frequently use high doses of anti-inflammatory drugs for a
             defined medication condition. Aspirin use should not exceed 2 tablets (650 mg) per
             day.

          -  Subjects currently receiving any anticancer, immunosuppressive treatments/ medications
             (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira,
             mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.), or radiation as
             determined by the initial paperwork.

          -  Subjects with a history of immunosuppression/immune deficiency disorders (including
             (HIV infection or AIDS) or currently using immunosuppressive medications (e.g.,
             azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate
             mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined
             by study documentation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoe D Draelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Consulting Services, High Point NC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zoe D Draelos, MD</last_name>
    <phone>336-841-2040</phone>
    <email>zdraelos@northstate.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hemali B Gunt, PhD</last_name>
    <phone>919-433-4131</phone>
    <email>hemali.gunt@burtsbees.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoe D Draelos, MD</last_name>
      <phone>336-841-2040</phone>
      <email>zdraelos@northstate.net</email>
    </contact>
    <investigator>
      <last_name>Zoe D Draelos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

